Advisors Preferred’s PDL BioPharma, Inc. PDLI Stock Holding History

Advisors Preferred’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,244	Closed	-$8K	–	291
2017 Q3	$8K	Buy	+2,244	New	+$6.24K	﹤0.01%	203
2016 Q2	–	Sell	-2,344	Closed	-$8K	–	337
2016 Q1	$8K	Buy	+2,344	New	+$7.31K	﹤0.01%	172
2015 Q4	–	Sell	-3,286	Closed	-$17K	–	286
2015 Q3	$17K	Buy	+3,286	New	+$18.8K	0.02%	113
2014 Q3	–	Sell	-12,554	Closed	-$122K	–	435
2014 Q2	$122K	Sell	12,554 -295	-2%	-$2.63K	0.06%	103
2014 Q1	$107K	Sell	12,849 -4,913	-28%	-$42.1K	0.05%	205
2013 Q4	$149K	Buy	+17,762	New	+$150K	0.08%	107

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Advisors Preferred's PDLI Position: Q4 2017 in Review

Advisors Preferred sold out of PDL BioPharma, Inc. (PDLI) in Q4 2017, closing a stake of 2,244 shares — an estimated $8K sold.

Advisors Preferred first reported a position in PDLI in Q4 2013 and held it in 6 quarters. The position peaked at $149K in Q4 2013. 187 funds tracked by Wall St. Rank hold PDLI as of Q4 2017.

Advisors Preferred reported no remaining PDL BioPharma, Inc. position as of Q4 2017 after selling out during the quarter.
Advisors Preferred sold 2,244 PDL BioPharma, Inc. shares in Q4 2017, an estimated $8K.
Advisors Preferred first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 6 quarters.
Advisors Preferred's PDL BioPharma, Inc. position peaked at $149K in Q4 2013.
187 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2017.

Based on Advisors Preferred's 13F filing for Q4 2017, filed 12 Feb 2018.